WO1997044028A1 - Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases - Google Patents

Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases Download PDF

Info

Publication number
WO1997044028A1
WO1997044028A1 PCT/US1997/008041 US9708041W WO9744028A1 WO 1997044028 A1 WO1997044028 A1 WO 1997044028A1 US 9708041 W US9708041 W US 9708041W WO 9744028 A1 WO9744028 A1 WO 9744028A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
treatment
furanone
cyclooxygenase
methylsulfonyl
Prior art date
Application number
PCT/US1997/008041
Other languages
French (fr)
Inventor
Bruno Hancock
Conrad Winters
Barry Gertz
Elliot Ehrich
Original Assignee
Merck & Co., Inc.
Merck Frosst Canada Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1997044028(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9612063.9A external-priority patent/GB9612063D0/en
Priority to AU30049/97A priority Critical patent/AU3004997A/en
Priority to SK1567-98A priority patent/SK284330B6/en
Priority to IL12689997A priority patent/IL126899A/en
Priority to US09/180,647 priority patent/US6063811A/en
Priority to EP97924688A priority patent/EP0910368A1/en
Priority to JP9542486A priority patent/JPH11512754A/en
Priority to BR9709097A priority patent/BR9709097A/en
Priority to NZ332670A priority patent/NZ332670A/en
Application filed by Merck & Co., Inc., Merck Frosst Canada Inc. filed Critical Merck & Co., Inc.
Priority to EE9800393A priority patent/EE03746B1/en
Priority to CA002254061A priority patent/CA2254061C/en
Priority to HU9902889A priority patent/HUP9902889A3/en
Priority to EA199801017A priority patent/EA001596B1/en
Priority to UA98126685A priority patent/UA51706C2/en
Publication of WO1997044028A1 publication Critical patent/WO1997044028A1/en
Priority to IS4891A priority patent/IS4891A/en
Priority to NO985342A priority patent/NO985342L/en
Priority to BG103000A priority patent/BG103000A/en
Priority to PL97329940A priority patent/PL188649B1/en
Priority to HK00100645A priority patent/HK1021623A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • This invention relates to pharmaceutical compositions for the treatment of cyclooxygenase-2 mediated diseases, mehe use of a compound in the manufacture of a medicament.
  • this invention relates to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day administration, said composition comprising a cyclooxygenase-2 inhibiting characterized by high potency for the inhibition of cyclooxygenase-2, a long half-life and a high degree of specificity for inhibiting cyclooxygenase-2 in preference to cyclooxygenase- 1.
  • a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases said composition being suitable for once a day administration
  • said composition comprising a cyclooxygenase-2 inhibiting characterized by high potency for the inhibition of cyclooxygenase-2, a long half-life and a high degree of specificity for inhibiting cyclooxygenase-2 in preference to cyclooxygenase- 1.
  • Such a compound is exemplified by 3- phenyl-4-(4-methylsulfonyl)
  • Non-steroidal anti-inflammatory agents are normally administered 2 to 4 times daily.
  • the relatively short half-life of most non-steroidal anti-inflammatory agents means that once a day administration is impractical and even twice a day administration is unusual.
  • the relatively large doses needed to achieve once a day treatment of conventional non-steroidal anti-inflammatory agents would also lead to side effects so that there is a general understanding that once a day administration is unlikely to be achievable.
  • a compound has been identified which can be employed on a once a day basis and which will not produce an unacceptable level of side effects on such a regimen, and in particular will not cause an unacceptable level of gastric side effects.
  • active agent possesses a half-life in humans of sufficient length that a single oral dose of 5 to 125 mg of agent per day will provide effective safe anti-inflammatory treatment over a 24 hour period.
  • active agents are particularly useful in the treatment of chronic indications, including arthritis, pain, Alzheimer's disease and the like.
  • This invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day oral administration, said composition comprising a cyclooxygenase-2 inhibiting compound characterized by high potency for the inhibition of cyclooxygenase-2, a long half-life and a high degree of specificity for inhibiting cyclooxygenase-2 in preference to cyclooxygenase- 1.
  • a compound is exemplified by 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5/0- furanone.
  • this invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day oral administration, said composition comprising 5 to 125 mgs of the above mentioned compound.
  • the invention is also directed to a method of treating cyclooxygenase-2 mediated diseases comprising the once a day oral administration of 5 to 125 mgs of the above mentioned compound.
  • the invention is also directed to the use the above mentioned compound in the manufacture of a medicament containing 5 to 125 mgs of said compound for once a day administration for the treatment of cyclooxygenase-2 mediated diseases.
  • this invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day administration, said composition comprising a cyclooxygenase-2 inhibitor characterized by high potency for the inhibition of cyclooxygenase-2, a long half-life and a high degree of specificity for inhibiting cyclooxygenase-2 in preference to cyclooxygenase- 1.
  • this invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day oral administration, said composition comprising a cyclooxygenase-2 inhibiting compound characterized by.
  • One such compound is 3-phenyl-4-(4- methylsulfonyl)phenyl)-2-(5H)-furanone,
  • this invention is directed only to compounds which act by inhibiting cyclooxygenase-2.
  • the characterization requirements set out above cannot be said to be met unless the mode of action of the compound is as an inhibitor of cyclooxygenase-2.
  • a central nervous system agent may relieve pain with a potency equal to or greater than ibuprofen, yet not meet the requirements set out above, because it does not act on cyclooxygenase-2. See Inflamm. Res. 45:68- 74 (1996) encorporated herein by reference, which discloses an (LPS)- challenge test for clinical identification and evaluation of cyclooxygenase-2 inhibition, and thromboxane B2 levels in the blood.
  • this invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day oral administration, said composition comprising a 5 to 125 mg of 3-phenyl- 4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone, and a pharmaceutical carrier therefor.
  • such a compound may inhibit cellular neoplastic transformations and metastic tumor growth and hence can be used in the treatment of cancer. It is also useful for the treatment of dementia including pre-senile and senile dementia, and in particular, dementia associated with Alzheimer Disease (ie Alzheimer's dementia).
  • the compound will also inhibit prostanoid-induced smooth muscle contraction by preventing the synthesis of contractile prostanoids and hence may be of use in the treatment of dysmenorrhea, premature labor and asthma.
  • the specified compound is also useful as an alternative to conventional non-steroidal antiinflammatory drugs (NSAID'S) particularly where such NSAIDS may be contra-indicated such as in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; GI bleeding, coagulation disorders including anemia such as hypoprothrombinemia, haemophilia or other bleeding problems (including those relating to reduced or impaired platelet function); kidney disease (eg impaired renal function); those prior to surgery or taking anticoagulants; and those susceptible to NSAID induced asthma.
  • NSAID'S non-steroidal antiinflammatory drugs
  • compositions for treating COX-2 mediated diseases as defined may optionally include one or more ingredients as listed above.
  • compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • the compositions are intended for oral use and may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
  • inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate
  • granulating and disintegrating agents for example, corn starch, or alginic acid
  • binding agents for example starch, gelatin or acacia
  • lubricating agents for example, magnesium stearate, stearic acid or talc.
  • 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5/_T)-furanone is particularly well suited for a rapid dissolving sublingual formulation.
  • the agent need not be take with a large amount of water.
  • Suitable Rapidisc® formulations and methods of making same are disclosed in US 4,305,502, US 4,371,516, US 4,470,202, US 4,758,598, US 4,754,597, US 5,046,618 and US 5,188,882, all of which are hereby inco ⁇ orated by reference.
  • Oral and intravenous dosage levels for agent 3-phenyl-4-(4- methylsulfonyl)phenyl)-2-(5//)-ruranone are of the order of from about 5 to 125 per patient per day.
  • the amount of active agent that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a formulation intended for the oral administration of humans may contain from 5 to 125 mg of agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
  • Dosage unit forms may typically contain 5, 10, 12.5, 20, 25, 50, 75, 100 or 125 mg of active agent.
  • the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination and the type and severity of the particular disease undergoing therapy.
  • a dosage range of 5 to 50 or 12.5 to 25 or 25 to 75 mg per day is preferred.
  • long term therapy such as in the treatment of chronic diseases including rheumatoid arthritis, osteoarthritis or Alzheimer disease, a dosage of 5 to 50 or 12.5 to 25 mg per day is preferred.
  • a dosage of 5, 10, 12.5, 25 or 50 mg per day is preferred, whereas for the treatment of rheumatoid arthritis, 10, 12.5, 25 or 50 mg per day is preferred.
  • 10, 12.5, 25 or 50 mg per day is preferred.
  • the invention is directed to a unit dose oral form which comprises from 5 to 50 or 5 to 22.5 mg of the cyclooxygenase inhibitor, for example, 12.5 or 20 mg or 12.5 to 25.
  • this invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition suitable for once a day oral administration, said composition comprising a 5 to 50 or 25 to 75 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone, and a pharmaceutical carried therefor.
  • compositions comprising 5 to 50 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5/f)- furanone.
  • second genus of compositions comprising 10 to 50 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2- (5i/)-furanone.
  • class of compositions comprising 5 to 22.5 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2- (5H)-furanone.
  • compositions comprising 12.5 to 25 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2- (5/f)-furanone.
  • compositions comprising 5, 10, 12.5, 25 or 50 mg of 3-phenyl-4-(4- methylsulfonyl)phenyl)-2-(5//)-furanone.
  • Tablet dose strengths of between 5 and 125 mg can be accomodated by varying total tablet weight, and the ratio of the first three ingredients. Generally it is preferable to maintain a 1 : 1 ratio for microcrystalline cellulose : lactose monohydrate.
  • Tablet dose strengths of between 5 and 125 mg can be accomodated by varying total tablet weight, and the ratio of the first three ingredients. Generally it is preferable to maintain a 1:1 ratio for microcrystalline cellulose : lactose monohydrate.
  • Capsule dose strengths of between 1 and 50 mg can be accomodated by varying total fill weight, and the ratio of the first three ingredients. Generally it is preferable to maintain a 1:1 ratio for microcrystalline cellulose : lactose monohydrate.
  • Solution dose strengths of between 1 and 50 mg/5mL can be accomodated by varying the ratio of the two ingredients.
  • Suspension dose strengths of between 1 and 50 mg/5ml can be accomodated by varying the ratio of the first two ingredients.
  • Step 2 3-0?henvn-4-(4-(methylsulfonvnphenylV2-f5/D-furanone To a solution of phenylacetic acid (27.4 g, 201 mmol) and
  • Step 1 2-bromo-l-(4-(methylsulfonyl)phenyl)ethanone (Step 1) (60 g, 216 mmol, 1.075 eq.) in acetonitrile (630 mL) at 25°C was added slowly Et3N (30.8 mL, 1.1 eq.). The mixture was stirred for 20 min. at r.t. and then cooled in an ice bath. DBU (60.1 mL, 3 eq.) was slowly added. After stirring for 20 min. in the ice bath, the reaction was complete and the mixture was acidified with IN HCI (color changed from dark brown to yellow).
  • MMPP magnesium monoperoxyphthalate
  • TMSC1 trimethylsilyl chloride

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day administration, said composition comprising a cyclooxygenase-2 inhibiting compound characterized by high potency, a long half-life and a high degree of specificity for inhibiting cyclooxygenase-2 in preference to cyclooxygenase-1. Such a compound is exemplified 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone. In one aspect, this invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day oral administration, said composition comprising 5 to 125 mgs of the above mentioned compound. The invention is also directed to a method of treating cyclooxygenase-2 mediated diseases comprising the once a day oral administration of 5 to 125 mgs of the above-mentioned compound. The invention is also directed to the use of the above-mentioned compound in the manufacture of a medicament containing 5 to 125 mgs of said compound for once a day administration for the treatment of cyclooxygenase-2 mediated diseases.

Description

TITLE OF THE INVENTION
COMPOSITIONS FOR A ONCE A DAY TREATMENT OF
CYCLOOXYGENASE-2 MEDIATED DISEASES
BACKGROUND OF THE INVENTION
This invention relates to pharmaceutical compositions for the treatment of cyclooxygenase-2 mediated diseases, mehe use of a compound in the manufacture of a medicament.
In particular, this invention relates to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day administration, said composition comprising a cyclooxygenase-2 inhibiting characterized by high potency for the inhibition of cyclooxygenase-2, a long half-life and a high degree of specificity for inhibiting cyclooxygenase-2 in preference to cyclooxygenase- 1. Such a compound is exemplified by 3- phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone,
Figure imgf000003_0001
Non-steroidal anti-inflammatory agents are normally administered 2 to 4 times daily. The relatively short half-life of most non-steroidal anti-inflammatory agents means that once a day administration is impractical and even twice a day administration is unusual. The relatively large doses needed to achieve once a day treatment of conventional non-steroidal anti-inflammatory agents would also lead to side effects so that there is a general understanding that once a day administration is unlikely to be achievable. Surprisingly a compound has been identified which can be employed on a once a day basis and which will not produce an unacceptable level of side effects on such a regimen, and in particular will not cause an unacceptable level of gastric side effects. US 5,474,995, issued December 12, 1995, WO 95/00501, published January 5, 1995 and WO 95/18799, published July 13, 1995, disclose 3,4-di-substituted furanones and derivatives thereof as potent, selective inhibitors of cyclooxygenase-2. We have found that 3-phenyl- 4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone, possesses a surprising combination of attributes that make it possible to formulate and use the composition in a surprising manner. Not only is the compound potent, safe and effective at modest oral dosages of 5 to 125 mg of agent per day, but in addition this active agent possesses a half-life in humans of sufficient length that a single oral dose of 5 to 125 mg of agent per day will provide effective safe anti-inflammatory treatment over a 24 hour period. Such active agents are particularly useful in the treatment of chronic indications, including arthritis, pain, Alzheimer's disease and the like.
SUMMARY OF THE INVENTION
This invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day oral administration, said composition comprising a cyclooxygenase-2 inhibiting compound characterized by high potency for the inhibition of cyclooxygenase-2, a long half-life and a high degree of specificity for inhibiting cyclooxygenase-2 in preference to cyclooxygenase- 1. Such a compound is exemplified by 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5/0- furanone. In one aspect, this invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day oral administration, said composition comprising 5 to 125 mgs of the above mentioned compound.
The invention is also directed to a method of treating cyclooxygenase-2 mediated diseases comprising the once a day oral administration of 5 to 125 mgs of the above mentioned compound.
The invention is also directed to the use the above mentioned compound in the manufacture of a medicament containing 5 to 125 mgs of said compound for once a day administration for the treatment of cyclooxygenase-2 mediated diseases.
DETAILED DESCRIPTION OF THE INVENTION
In one embodiment, this invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day administration, said composition comprising a cyclooxygenase-2 inhibitor characterized by high potency for the inhibition of cyclooxygenase-2, a long half-life and a high degree of specificity for inhibiting cyclooxygenase-2 in preference to cyclooxygenase- 1.
In one genus, of this embodiment, this invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day oral administration, said composition comprising a cyclooxygenase-2 inhibiting compound characterized by.
(a) high potency for the inhibition of cyclooxygenase-2 as measured by the ability of a single therapeutic dose of said compound to provide relief from the post-operative pain accompanying the removal of two or three molars, said relief being statistically equal to or greater than that obtained with a single dose of 400 mg of ibuprofen;
(b) a half-life or 9 or more hours, preferably 15 hours or more and more preferably 18 hours or more; and
(c) a high degree of specificity for inhibiting cyclooxygenase-2 in preference to cyclooxygenase- 1 as measured by the statistical failure of a therapeutic dose of said compound to inhibit the generation of serum thromboxane B2.
One such compound is 3-phenyl-4-(4- methylsulfonyl)phenyl)-2-(5H)-furanone,
Figure imgf000006_0001
As will be appreciated by those of skill in the art, this invention is directed only to compounds which act by inhibiting cyclooxygenase-2. Thus, the characterization requirements set out above cannot be said to be met unless the mode of action of the compound is as an inhibitor of cyclooxygenase-2. For example, a central nervous system agent may relieve pain with a potency equal to or greater than ibuprofen, yet not meet the requirements set out above, because it does not act on cyclooxygenase-2. See Inflamm. Res. 45:68- 74 (1996) encorporated herein by reference, which discloses an (LPS)- challenge test for clinical identification and evaluation of cyclooxygenase-2 inhibition, and thromboxane B2 levels in the blood. Equivalent tests may also be used. Compounds of the instant invention are not hepatotoxic at therapeutic doses. Moreover, compounds of the instant invention demonstrate an ED30 in the rat paw edema assay of 0.4 mg/kg or less when measured as disclosed in WO 95/00501 and a selectivity for the inhibition of COX-2 over COX-1 of 50:1 or more measured as disclosed on WO 95/00501.
In one embodiment, this invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day oral administration, said composition comprising a 5 to 125 mg of 3-phenyl- 4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone, and a pharmaceutical carrier therefor.
3-Phenyl-4-(4-methylsulfonyl)phenyl)-2-(5/ιr)-furanone, its utility and methods of making them are disclosed in US 5,474,995, issued December 12, 1995, WO 95/00501, published January 5, 1995 and WO 95/18799, published July 13, 1995, which are hereby incoφorated by reference.
As discussed in US 5,474,995 compounds, including 3- phenyl-4-(4-memylsulfonyl)phenyl)-2-(5/ϊ)-furanone, are useful for the relief of pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns, injuries following surgical and dental procedures. In addition, such a compound may inhibit cellular neoplastic transformations and metastic tumor growth and hence can be used in the treatment of cancer. It is also useful for the treatment of dementia including pre-senile and senile dementia, and in particular, dementia associated with Alzheimer Disease (ie Alzheimer's dementia).
The compound will also inhibit prostanoid-induced smooth muscle contraction by preventing the synthesis of contractile prostanoids and hence may be of use in the treatment of dysmenorrhea, premature labor and asthma.
By virtue of its high cyclooxygenase-2 (COX-2) inhibitory activity and/or its selectivity for inhibiting COX-2 over cyclooxygenase- 1 (COX-1) the specified compound is also useful as an alternative to conventional non-steroidal antiinflammatory drugs (NSAID'S) particularly where such NSAIDS may be contra-indicated such as in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; GI bleeding, coagulation disorders including anemia such as hypoprothrombinemia, haemophilia or other bleeding problems (including those relating to reduced or impaired platelet function); kidney disease (eg impaired renal function); those prior to surgery or taking anticoagulants; and those susceptible to NSAID induced asthma.
For the treatment of any of these cyclooxygenase mediated diseases the compound may be administered orally or by intravenous infusion. As indicated above, pharmaceutical compositions for treating COX-2 mediated diseases as defined may optionally include one or more ingredients as listed above.
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. The compositions are intended for oral use and may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
Other suitable formulations are set forth in U.S. Patent No. 5,474,995. However, in view of the unique set of properties possessed by 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5.¥)-furanone, including long half-life, low solubility, high potency, de minimis gastrointestinal (GI) side effects, we have found the following oral formulations to be of particular value: Rapidisc® - In view of the above mentioned characteristics,
3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5/_T)-furanone is particularly well suited for a rapid dissolving sublingual formulation. For example, due to the lack of GI side-effects, the agent need not be take with a large amount of water. Suitable Rapidisc® formulations and methods of making same are disclosed in US 4,305,502, US 4,371,516, US 4,470,202, US 4,758,598, US 4,754,597, US 5,046,618 and US 5,188,882, all of which are hereby incoφorated by reference.
As mentioned in the Background section, we have found 3- phenyl-4-(4-methylsulfonyl)phenyl)-2-(5//)-furanone to possess a suφrising combination of attributes. Not only are these active agents potent safe and effective at modest oral dosages of 5 to 125 mg of agent per day, but in addition these active agents possess a half-life in humans of sufficient length that a single oral dose of 5 to 125 mg of active agent per day will provide effective safe anti-inflammatory treatment over a 24 hour period. Such agents are particularly useful in the treatment of chronic indications, such as rheumatoid and osteo arthritis as well as Alzheimer's Disease.
Oral and intravenous dosage levels for agent 3-phenyl-4-(4- methylsulfonyl)phenyl)-2-(5//)-ruranone are of the order of from about 5 to 125 per patient per day.
The amount of active agent that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 5 to 125 mg of agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms may typically contain 5, 10, 12.5, 20, 25, 50, 75, 100 or 125 mg of active agent.
It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination and the type and severity of the particular disease undergoing therapy. For many patients, a dosage range of 5 to 50 or 12.5 to 25 or 25 to 75 mg per day is preferred. For long term therapy, such as in the treatment of chronic diseases including rheumatoid arthritis, osteoarthritis or Alzheimer disease, a dosage of 5 to 50 or 12.5 to 25 mg per day is preferred. More particularly, for the treatment of osteoarthritis, a dosage of 5, 10, 12.5, 25 or 50 mg per day is preferred, whereas for the treatment of rheumatoid arthritis, 10, 12.5, 25 or 50 mg per day is preferred. For the treatment of non-chronic indications such as headache or post¬ operative swelling and pain, 10, 12.5, 25 or 50 mg per day is preferred.
Accordingly, in one aspect the invention is directed to a unit dose oral form which comprises from 5 to 50 or 5 to 22.5 mg of the cyclooxygenase inhibitor, for example, 12.5 or 20 mg or 12.5 to 25. In another aspect this invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition suitable for once a day oral administration, said composition comprising a 5 to 50 or 25 to 75 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone, and a pharmaceutical carried therefor.
Within this aspect there is a first genus of compositions comprising 5 to 50 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5/f)- furanone. Within this aspect there is a second genus of compositions comprising 10 to 50 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2- (5i/)-furanone. Within this genus there is a class of compositions comprising 5 to 22.5 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2- (5H)-furanone.
Within this genus there is a class of compositions comprising 12.5 to 25 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2- (5/f)-furanone.
Within this genus there is a class of compositions comprising 5, 10, 12.5, 25 or 50 mg of 3-phenyl-4-(4- methylsulfonyl)phenyl)-2-(5//)-furanone.
EXAMPLE 1
Wet granulated tablet composition
Amount per tablet Ingredient
25 mg COX-2 Inhibitor
79.7 mg Microcrystalline cellulose
79.7 mg Lactose monohydrate 6 mg Hydroxypropyl cellulose
8 mg Croscarmellose sodium
0.6 mg Iron oxide
1 mg Magnesium stearate
Tablet dose strengths of between 5 and 125 mg can be accomodated by varying total tablet weight, and the ratio of the first three ingredients. Generally it is preferable to maintain a 1 : 1 ratio for microcrystalline cellulose : lactose monohydrate.
EX AMPLE la
Wet granulated tablet composition
Amount per tablet Ingredient
12.5 mg COX-2 Inhibitor
86 mg Microcrystalline cellulose
86 mg Lactose monohydrate 6 mg Hydroxypropyl cellulose
8 mg Croscarmellose sodium
0.6 mg Iron oxide
1 mg Magnesium stearate
EXAMPLE lb
Wet granulated tablet composition
Amount per tablet Ingredient
10 mg COX-2 Inhibitor
87.2 mg Microcrystalline cellulose
87.2 mg Lactose monohydrate
6 mg Hydroxypropyl cellulose 8 mg Croscarmellose sodium
0.6 mg Iron oxide
1 mg Magnesium stearate
EXAMPLE lc
Wet granulated tablet composition
Amount per tablet Ingredient
5 mg COX-2 Inhibitor
89.7 mg Microcrystalline cellulose
89.7 mg Lactose monohydrate
6 mg Hydroxypropyl cellulose 8 mg Croscarmellose sodium
0.6 mg Iron oxide
1 mg Magnesium stearate
EXAMPLE 2
Directly compressed tablet composition
Amount per tablet Ingredient
25 mg COX-2 Inhibitor
106.9 mg Microcrystalline cellulose
106.9 mg Lactose anhydrate
7.5 mg Crosmellose sodium
3.7 mg Magnesium stearate
Tablet dose strengths of between 5 and 125 mg can be accomodated by varying total tablet weight, and the ratio of the first three ingredients. Generally it is preferable to maintain a 1:1 ratio for microcrystalline cellulose : lactose monohydrate.
EXAMPLE 2a
Directly compressed tablet composition
Amount per tablet Ingredient
12.5 mg COX-2 Inhibitor
113.2 mg Microcrystalline cellulose
113.2 mg Lactose anhydrate 7.5 mg Croscarmellose sodium
3.7 mg Magnesium stearate
EXAMPLE 2h
Directly compressed tablet composition
Amount per tablet Ingredient 10 mg COX-2 Inhibitor
42.5 mg Microcrystalline cellulose
42.5 mg Lactose anhydrate
4 mg Croscarmellose sodium 1 mg Magnesium stearate
EXAMPLE 2c
Directly compressed tablet composition
Amount per tablet Ingredient
5 mg COX-2 Inhibitor
45 mg Microcrystalline cellulose 45 mg Lactose anhydrate
4 mg Croscarmellose sodium
1 mg Magnesium stearate
EXAMPLE 3 •
Hard gelatin capsule composition
Amount per capsule Ingredient
25 mg COX-2 Inhibitor
37 mg Microcrystalline cellulose
37 mg Lactose anhydrate
1 mg Magnesium stearate
1 capsule Hard gelatin capsule
Capsule dose strengths of between 1 and 50 mg can be accomodated by varying total fill weight, and the ratio of the first three ingredients. Generally it is preferable to maintain a 1:1 ratio for microcrystalline cellulose : lactose monohydrate. EXAMPLE 4
Oral solution
Amount per 5 mL dose Ingredient
50 mg COX-2 Inhibitor to 5 mL with Polyethylene oxide 400
Solution dose strengths of between 1 and 50 mg/5mL can be accomodated by varying the ratio of the two ingredients.
EXAMPLE 5
Oral suspension
Amount per 5 mL dose Ingredient
101 mg COX-2 Inhibitor 150 mg Poly vinylpyrrolidone
2.5 mg Poly oxyethylene sorbitan monolaurate
10 mg Benzoic acid to 5 mL with sorbitol solution (70%)
Suspension dose strengths of between 1 and 50 mg/5ml can be accomodated by varying the ratio of the first two ingredients.
EXAMPLE 6
Intravenous infusion
Amount per 200mL dose Ingredient
1 mg COX-2 inhibitor 0.2 mg Polyethylene oxide 400 1.8 mg Sodium chloride to 200mL Purified water STARTING MATERIALS
PREPARATION 1 3-(Phenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5/f)-furanone Step 1: 2-Bromo- 1 -(4-(methvlsulfonvl)phenvnethanone
A solution of 197 g of 4-(methylthio)acetophenone (ref: J.Am.Chem.Soc, 1952, Jά, p. 5475) in 700 mL of MeOH and 3500mL of CH2CI2 was added 881 g of MMPP over a period of 30 min. After 3 h at r.t. the reaction mixture was filtered and the filtrate was washed with 2 L of saturated aqueous solution of NaHCθ3 and 1 L of brine. The aqueous phase was further extracted with 2 L of CH2CI2. The combined extracts were dried over Na2Sθ4 concentrated to give 240 g of 4-(methylsulfonyl)acetophenone as a white solid. To a cooled (-5 °C) solution of 174 g of 4-(methylsulfonyl)- acetophenone in 2.5 L of CHCI3 was added 20 mg of AICI3, followed by a solution of 40 mL of Br2 in 300 mL CHCI3. The reaction mixture was then treated with 1.5 L of H2O and the CHCI3 was separated. The aqueous layer was extracted with 1 L of EtOAc. The combined organic extracts were dried over Na2Sθ4 and concentrated. The crude product was recystallized from 50/50 EtOAc/hexane to give 210 g of the title compound as a white solid.
Step 2: 3-0?henvn-4-(4-(methylsulfonvnphenylV2-f5/D-furanone To a solution of phenylacetic acid (27.4 g, 201 mmol) and
2-bromo-l-(4-(methylsulfonyl)phenyl)ethanone (Step 1) (60 g, 216 mmol, 1.075 eq.) in acetonitrile (630 mL) at 25°C was added slowly Et3N (30.8 mL, 1.1 eq.). The mixture was stirred for 20 min. at r.t. and then cooled in an ice bath. DBU (60.1 mL, 3 eq.) was slowly added. After stirring for 20 min. in the ice bath, the reaction was complete and the mixture was acidified with IN HCI (color changed from dark brown to yellow). Then 2.4 L of ice and H2O were added, the mixture was stirred for a few minutes, and the precipitate was filtered and rinsed with H2θ, giving 64 g of crude wet product. The solid was dissolved in 750 mL of CH2CI2, dried over MgSOφ filtered and 300 g of silica gel was added to the filtrate. The solvent was evaporated to near dryness (silica gel a bit sticky), the residue was applied on top of a silica gel plug in a sintered glass funnel and eluted with 10% EtOAc/CH2θ2, giving after evaporation of the solvent and swishing in EtOAc, 36.6 g (58%) of the title compound.
Analysis: Calculated for C17H14O4S: C, 64.95; H, 4.49; S, 10.20 Found: C, 64.63; H, 4.65; S, 10.44
PREPARATION 2
3-fPhenyl)-4-(4-fmethylsulfonyl)phenyD-2-(5H)-furanone Into a 20 mL glass ampule are added 1 g of 2-(4-
(methylsulfonyl)phenyl)phenylacetylene (J.Am.Chem.Soc, 1971, ££ , p. 2979), 20 mg of Rh4(CO)i2, 1.5 g of Et3N, 10 mL of THF, and 1 mL of H2θ under a nitrogen atmosphere, and the ampule is placed in a 100- rnL stainless steel autoclave. The reaction system is flushed three times with CO then charged at r.t. to an initial CO pressure of 100 atm. The reaction is carried out at 100°C for 5 h. The solution is then diluted with 50 mL of benzene and washed with brine and IN HCI. The benzene solution is dried over Na2Sθ4, and concentrated. The crude products are separated by column chromatography on silica gel, eluting with 2: 1 EtOAc/hexane to give the title compound and its regioisomer.
PREPARATION 3
3-(Phenyl)-4-(4-(methylsulfonyDphenyl)-2-(5//)-furanone Step 1: 2-trimethylsilyloxy-4-(4-(methylthio)phenylV3.4- dihvdrofuran To a solution of 3.86 g (19 mmol) of 4-bromothioanisole in 90 mL of Et2θ cooled at -78°C, is added 22 mL of a 1.7 M solution of t-BuLi in pentane (38 mmol) dropwise. The reaction mixture is stirred for 15 min at -78°C and 3.8 g of Cul is added and the reaction mixture is allowed to warm to -40°C over a period of 30 min. A solution of 1.7 g of 2(5#)-furanone in 10 mL of THF is added. After stirring for 1 h, 2 mL of freshly distilled TMSC1 is added dropwise. The reaction mixture is then treated with 2 mL of Et3N and 50 mL of sat. NaHCθ3, and extracted with 100 mL of Et2θ. The Et2θ layer is dried over Na2S04 and concentrated to give the crude title compound which is used for the next step without further purification.
Step 2: 4-(4-(Methylthio)phenylV2-(5*/Vfuranone
To a solution of 4 g of Pd(OAc)2 in 100 mL of acetonitrile is added dropwise the crude product from Step 1(5 g) under nitrogen at r.t. After 10 h at r.t., the mixture is concentrated under reduced pressure and the residue is purified by flash chromatography on silica gel eluted with 2:1 hexane/EtOAc to give the title compound.
Step 3: 3-Iodo-4-(4-fmethylthio)phenylV2-(5if,-furanone
To a solution of 3 g of the product of Step 2 in 30 mL of pyridine is added 8.7 g of I2. The mixture is stirred for 24 h and then diluted with 200 mlL of Et2θ, washed with 100 mL of 5N HCI and 50 mL of 5N Na2S2θ3. The Et2θ layer is dried over Na2Sθ4 and concentrated to give the title compound.
Step 4: 3-(PhenylV4-f4-fmethylthio)phenylV2-(5H)-furanone
A mixture of 4 g of the product of Step 3, 3.7 g of PhB(OH)2, 0.4 g of Ph3As, 0.4 g of PdCl2(PhCN)2 in 100 mL of benzene and 15 mL of 2N NaOH is refluxed for 6 h. After cooling to r.t., Et2θ (200 mL) is added to the reaction mixture and the mixture is washed with 100 mL of saturated NaHCθ3. The organic layer is dried over MgSθ4 and concentrated. The residue is purified by flash chromatography on silica gel eluted with 4: 1 hexane/EtOAc to give the title compound.
Step 5: 3-ΦhenvIV4-(4-ιmethylsulfonyl)phenyl)-2-(5flVfuranone
To a solution of 3 g of the product of Step 4 in 80 mL of
10:1 CH2Cl2/MeOH is added 5.5 g of MMPP. The reaction mixture is stirred at r.t. for 2 h and then diluted with 100 mL of 1:1 hexane/EtOAc. After filtration and concentration, the residue is purified by flash chromatography eluted with 2: 1 EtOAc/hexane to give the title product.
ABBREVIATIONS
DBU = l,8-diazabicyclo[5.4.0]undec-7-ene Et3N = triethylamine
MMPP = magnesium monoperoxyphthalate
THF = tetrahydrofuran
TMSC1 = trimethylsilyl chloride

Claims

WHAT IS CLAIMED IS:
1. A pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day oral administration, said composition comprising 5 to 125 mg of a compound is 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5//)- furanone.
2. A composition according to Claim 1 comprising 5, 10, 12.5 or 25 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)- furanone.
3. A composition according to Claim 1 comprising 10 to 125 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5//)-furanone.
4. A composition according to Claim 1 comprising 10 to 75 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5/ιf)-furanone.
5. A composition according to Claim 1 comprising 10, 25, or 50 mg of 3-ρhenyl-4-(4-methylsulfonyl)phenyl)-2-(5//)-furanone.
6. A composition according to Claim 1 comprising 25, 50 or 75 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5J/)-furanone.
7. A pharmaceutical composition according to Claim 1,
2, 3, 4, 5, or 6 further comprising
(a) Microcrystalline cellulose,
(b) Lactose monohydrate,
(c) Hydroxypropyl cellulose, (d) Croscarmellose sodium,
(e) Iron oxide, and
(f) Magnesium stearate; or further comprising
(a) Microcrystalline cellulose, (b) Lactose anhydrate,
(c) Croscarmellose sodium, and
(d) Magnesium stearate; or further comprising
Polyethylene oxide 400; or further comprising
(a) Sorbitol solution,
(b) Polyvinylpyrrolidone,
(c) Poly oxyethylene sorbitan monolaurate, and (d) Benzoic acid.
8. A method of treating an inflammatory disease susceptible to treatment with an non-steroidal anti-inflammatory agent comprising: administration orally once a day to a patient in need of such treatment 5 to 125 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5#)-furanone.
9. A method according to Claim 8 comprising: administration orally once a day to a patient in need of such treatment 5, 10, 12.5 or 25 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5#)- furanone.
10. A method according to Claim 8 comprising: administration orally once a day to a patient in need of such treatment 10 to 125 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5//)- furanone.
11. A method according to Claim 8 comprising: administration orally once a day to a patient in need of such treatment 10 to 75 mg of 3-phenyl-4-(4-methylsulfonyl)ρhenyl)-2-(5H)-furanone.
12. A method according to Claim 8 comprising: administration orally once a day to a patient in need of such treatment 10, 25 or 50 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5#)- furanone.
13. A method according to Claim 8 comprising: administration orally once a day to a patient in need of such treatment 25, 50 or 75 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5//)- furanone.
14. A method of treating an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent comprising: administration orally once a day to a patient in need of such treatment a composition according to Claim 7.
15. A method according to Claim 9 for the treatment of non-chronic headache, pain or swelling.
16. A method according to Claim 12 for the treatment of osteoarthritis.
17. A method according to Claim 13 for the treatment of rheumatoid arthritis.
18. Use of 5 to 125 mg of 3-phenyl-4-(4-methyl- sulfonyl)phenyl)-2-(5//)-furanone in the manufacture of a once a day oral dosage form of a medicament for the treatment of an inflammatroy disease susceptible to treatment with a non-steroidal anti-inflammatory agent.
19. Use according to Claim 18 of 5, 10, 12.5 or 25 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5//)-furanone in the
SUBSTITUTE SHEET (RUli 28) manufacture of a once a day oral dosage form of a medicament for the treatment of an inflammatroy disease susceptible to treatment with a non-steroidal anti-inflammatory agent.
20. Use according to Claim 18 of 10 to 125 mg of 3- phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone in the manufacture of a once a day oral dosage form of a medicament for the treatment of an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent.
21. Use according to Claim 18 of 10 to 75 mg of 3- phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone in the manufacture of a once a day oral dosage form of a medicament for the treatment of an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent.
22. Use according to Claim 18 of 10, 12.5, 25 or 50 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5//)-furanone in the manufacture of a once a day oral dosage form of a medicament for the treatment of an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent.
23. Use according to Claim 18 of 10, 12.5, 25 or 50 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone in the manufacture of a once a day oral dosage form of a medicament for the treatment of osteoarthritis.
24. Use according to Claim 18 of 25, 50 or 75 mg of 3- phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone in the manufacture of a once a day oral dosage form of a medicament for the treatment of an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent.
SUBSTITUTE SHEH (RULE 26)
25. Use according to Claim 18 of 25, 50 or 75 mg of 3- phenyl-4-(4-methylsulfonyl)phenyl)-2-(5//)-furanone in the manufacture of a once a day oral dosage form of a medicament for the treatment of rheumatoid arthritis.
26. Use according to Claim 18 of 5, 10, 12.5 or 25 mg of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5//)-furanone in the manufacture of a once a day oral dosage form of a medicament for the treatment of non-chronic headache, pain or swelling.
27. A pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day administration, said composition comprising a cyclooxygenase-2 inhibiting compound characterized by
(a) high potency for the inhibition of cyclooxygenase-2 as measured by the ability of a single therapeutic dose of said compound to provide relief from the post-operative pain accompanying the removal of two or three molars, said relief being statistically equal to or greater than that obtained with a single dose of 400 mg of ibuprofen;
(b) a half-life or 15 hours or more; and
(c) a high degree of specificity for inhibiting cyclooxygenase-2 in preference to cyclooxygenase- 1 as measured by the statistical failure of a therapeutic dose of said compound to inhibit the generation of serum thromboxane B2.
28. A composition according to Claim 27 comprising 5, 10, 12.5 or 25 mg of said cyclooxygenase-2 inhibitor.
29. A composition according to Claim 27 comprising 10 to 125 mg of said cyclooxygenase-2 inhibitor.
30. A composition according to Claim 27 comprising 10 to 75 mg of said cyclooxygenase-2 inhibitor.
31. A composition according to Claim 27 comprising 10, 25, or 50 mg of said cyclooxygenase-2 inhibitor.
32. A composition according to Claim 27 comprising 25, 50 or 75 mg of said cyclooxygenase-2 inhibitor.
33. A pharmaceutical composition according to Claim
27, 28, 29, 30, 31, or 32 further comprising
(a) Microcrystalline cellulose,
(b) Lactose monohydrate,
(c) Hydroxypropyl cellulose, (d) Croscarmellose sodium,
(e) Iron oxide, and
(f) Magnesium stearate; or further comprising
(a) Microcrystalline cellulose, (b) Lactose anhydrate,
(c) Croscarmellose sodium, and
(d) Magnesium stearate; or further comprising
Polyethylene oxide 400; or further comprising
(a) Sorbitol solution,
(b) Polyvinylpyrrolidone,
(c) Poly oxyethylene sorbitan monolaurate, and
(d) Benzoic acid.
34. A unit dose oral form which comprises from 5 to 22.5 mg of the cyclooxygenase inhibitor characterized by
(a) high potency for the inhibition of cyclooxygenase-2 as measured by the ability of a single therapeutic dose of said compound to provide relief from the post-operative pain accompanying the removal of two or three molars, said relief being statistically equal to or greater than that obtained with a single dose of 400 mg of ibuprofen;
(b) a half-life or 15 hours or more; and
(c) a high degree of specificity for inhibiting cyclooxygenase-2 in preference to cyclooxygenase- 1 as measured by the statistical failure of a therapeutic dose of said compound to inhibit the generation of serum thromboxane B2.
35. A unit dosage form according to Claim 34 which comprises 12.5 or 20 mg of the cyclooxygense-2 inhibitor.
36. A unit dosage form according to Claim 35 which comprises 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone.
PCT/US1997/008041 1996-05-17 1997-05-13 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases WO1997044028A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
EA199801017A EA001596B1 (en) 1996-05-17 1997-05-13 Compositions for the treatment of cyclooxygenase-2 mediated diseases and method of treating an inflammatory disease
UA98126685A UA51706C2 (en) 1996-05-17 1997-05-13 Method for treating inflammatory diseases by administering 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5h)-furanone
EE9800393A EE03746B1 (en) 1996-05-17 1997-05-13 A pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, the use of 3-phenyl-4- (4- (methylsulfonyl) phenyl) -2- (5H) -furanone, and a unit oral dosage form
IL12689997A IL126899A (en) 1996-05-17 1997-05-13 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
US09/180,647 US6063811A (en) 1996-05-17 1997-05-13 Compositions for a once day treatment of cyclooxygenase-2 mediated diseases
EP97924688A EP0910368A1 (en) 1996-05-17 1997-05-13 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
JP9542486A JPH11512754A (en) 1996-05-17 1997-05-13 Composition for once-daily treatment of cyclooxygenase-2-mediated disease
BR9709097A BR9709097A (en) 1996-05-17 1997-05-13 Pharmaceutical composition for the treatment of diseases mediated by cyclooxygenase process to treat an inflammatory disease susceptible to treatment with an anti-inflammatory agent in the steroid use and oral form of unit dose
NZ332670A NZ332670A (en) 1996-05-17 1997-05-13 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases comprising 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone
AU30049/97A AU3004997A (en) 1996-05-17 1997-05-13 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
SK1567-98A SK284330B6 (en) 1996-05-17 1997-05-13 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
CA002254061A CA2254061C (en) 1996-05-17 1997-05-13 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
HU9902889A HUP9902889A3 (en) 1996-05-17 1997-05-13 The use of 3-phenyl-4-(4-methylsulphonyl)-phenyl-2-(5h)-furanone for producing anti inflammatory medicaments and such medicaments
IS4891A IS4891A (en) 1996-05-17 1998-11-10 Compositions for once-daily treatment of cyclooxygenase-2-dependent diseases
NO985342A NO985342L (en) 1996-05-17 1998-11-16 Preparation for treatment Once per. day of cyclooxygenase-2-mediated diseases
BG103000A BG103000A (en) 1996-05-17 1998-12-08 Compositions for single daily dosage in the treatment of cyclooxygenase-2-dependent diseases
PL97329940A PL188649B1 (en) 1996-05-17 1999-01-11 Compositions for once-a-day administration for use in treating diseases involving mediator effect of cyclooxygenase-2
HK00100645A HK1021623A1 (en) 1996-05-17 2000-02-02 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1787896P 1996-05-17 1996-05-17
US60/017,878 1996-05-17
GBGB9612063.9A GB9612063D0 (en) 1996-06-10 1996-06-10 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
GB9612063.9 1996-06-10

Publications (1)

Publication Number Publication Date
WO1997044028A1 true WO1997044028A1 (en) 1997-11-27

Family

ID=26309472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/008041 WO1997044028A1 (en) 1996-05-17 1997-05-13 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases

Country Status (29)

Country Link
US (1) US6063811A (en)
EP (1) EP0910368A1 (en)
JP (1) JPH11512754A (en)
KR (1) KR100373622B1 (en)
CN (1) CN1140267C (en)
AR (1) AR012014A1 (en)
AU (1) AU3004997A (en)
BG (1) BG103000A (en)
BR (1) BR9709097A (en)
CA (1) CA2254061C (en)
CO (1) CO5050370A1 (en)
CZ (1) CZ291463B6 (en)
DZ (1) DZ2200A1 (en)
EA (1) EA001596B1 (en)
EE (1) EE03746B1 (en)
HK (1) HK1021623A1 (en)
HR (1) HRP970262A2 (en)
HU (1) HUP9902889A3 (en)
ID (1) ID16921A (en)
IL (1) IL126899A (en)
IS (1) IS4891A (en)
MY (1) MY116201A (en)
NO (1) NO985342L (en)
NZ (1) NZ332670A (en)
PE (1) PE66998A1 (en)
PL (1) PL188649B1 (en)
SK (1) SK284330B6 (en)
TR (1) TR199802345T2 (en)
WO (1) WO1997044028A1 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1049467A1 (en) * 1998-11-30 2000-11-08 G.D. Searle & Co. Celecoxib compositions
EP1061908A1 (en) * 1998-03-13 2000-12-27 Merck & Co., Inc. Combination therapy and composition for acute coronary ischemic syndrome and related conditions
WO2001015664A2 (en) * 1999-08-31 2001-03-08 Bradford Particle Design Limited Coformulation methods and their products
WO2001045705A1 (en) * 1999-12-22 2001-06-28 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
WO2002015886A2 (en) * 2000-08-18 2002-02-28 Pharmacia Corporation Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor
WO2002015884A2 (en) * 2000-08-18 2002-02-28 Pharmacia Corporation Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
WO2002056878A2 (en) * 2001-01-18 2002-07-25 Pharmacia Corporation Pharmaceutical composition having reduced tendency for drug crystallization
WO2003026697A2 (en) * 2001-09-26 2003-04-03 Pharmacia Corporation Organoleptically acceptable intraorally disintegrating compositions
WO2003030876A1 (en) * 2001-10-10 2003-04-17 Pharmacia Corporation Intraorally disintegrating valdecoxib compositions prepared by spray drying process
ES2214129A1 (en) * 2003-02-13 2004-09-01 Almirall Prodesfarma, S.A. 3-phenylfuran-2-one derivatives as cox-2 inhibitor
JP2004527458A (en) * 2000-09-11 2004-09-09 ノバルティス アクチエンゲゼルシャフト Pharmaceutical composition
WO2005025564A1 (en) * 2003-09-18 2005-03-24 Nobel Ilac Sanayii A.S Oral pharmaceutical formulations of rofecoxib
JP2005520785A (en) * 2001-08-31 2005-07-14 ノバルティス アクチエンゲゼルシャフト Lumiracoxib-containing pharmaceutical composition
US6924303B2 (en) 2000-06-13 2005-08-02 Wyeth Analgesic and anti-inflammatory compositions containing COX-2 inhibitors
US7582676B2 (en) 2003-02-13 2009-09-01 Laboratorios Almirall, S.A. 2-phenylpyran-4-one derivatives as selective COX-2 inhibitors
US8541471B2 (en) 2003-05-07 2013-09-24 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US10987337B2 (en) 2018-11-21 2021-04-27 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
US11858909B2 (en) 2021-04-09 2024-01-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
CO5190664A1 (en) 1999-06-30 2002-08-29 Pfizer Prod Inc COMBINATION THERAPY FOR THE TREATMENT OF MIGRANA ADMINISTRATION OF A 5HT RECEPTOR, CAFFEINE AND A CYCLLOXYGENASA-2 INHIBITOR
US8680081B2 (en) * 2000-08-29 2014-03-25 Peter Van Patten Prophylactic treatment of migraine
JP2005503346A (en) * 2001-05-04 2005-02-03 メルク　エンド　カムパニー　インコーポレーテッド Methods and compositions for treating migraine
PE20040288A1 (en) * 2002-03-07 2004-06-24 Novartis Ag PHARMACEUTICAL COMPOSITIONS OF 5-METHYL-2- (2'-CHLORO-6'-FLUOROANILINO) PHENYLACETIC ACID
WO2008091530A2 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
US20200323830A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with etoricoxib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000501A2 (en) * 1993-06-24 1995-01-05 Merck Frosst Canada Inc. Phenyl heterocycles as cyclooxygenase-2 inhibitors
WO1995018799A1 (en) * 1994-01-10 1995-07-13 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000501A2 (en) * 1993-06-24 1995-01-05 Merck Frosst Canada Inc. Phenyl heterocycles as cyclooxygenase-2 inhibitors
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
WO1995018799A1 (en) * 1994-01-10 1995-07-13 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1061908A4 (en) * 1998-03-13 2007-01-24 Merck & Co Inc Combination therapy and composition for acute coronary ischemic syndrome and related conditions
EP1061908A1 (en) * 1998-03-13 2000-12-27 Merck & Co., Inc. Combination therapy and composition for acute coronary ischemic syndrome and related conditions
US9750756B2 (en) 1998-11-30 2017-09-05 Pfizer Inc. Celecoxib compositions
EP1049467A1 (en) * 1998-11-30 2000-11-08 G.D. Searle & Co. Celecoxib compositions
EP1049467A4 (en) * 1998-11-30 2001-08-08 Searle & Co Celecoxib compositions
WO2001015664A3 (en) * 1999-08-31 2001-09-20 Bradford Particle Design Plc Coformulation methods and their products
WO2001015664A2 (en) * 1999-08-31 2001-03-08 Bradford Particle Design Limited Coformulation methods and their products
WO2001045705A1 (en) * 1999-12-22 2001-06-28 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
US6924303B2 (en) 2000-06-13 2005-08-02 Wyeth Analgesic and anti-inflammatory compositions containing COX-2 inhibitors
US7754753B2 (en) 2000-06-13 2010-07-13 Wyeth Llc Analgesic and anti-inflammatory compositions containing Cox-2-inhibitors
WO2002015886A3 (en) * 2000-08-18 2002-07-25 Pharmacia Corp Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor
WO2002015884A3 (en) * 2000-08-18 2002-07-25 Pharmacia Corp Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
WO2002015884A2 (en) * 2000-08-18 2002-02-28 Pharmacia Corporation Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
WO2002015886A2 (en) * 2000-08-18 2002-02-28 Pharmacia Corporation Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor
JP2004527458A (en) * 2000-09-11 2004-09-09 ノバルティス アクチエンゲゼルシャフト Pharmaceutical composition
WO2002056878A3 (en) * 2001-01-18 2002-12-19 Pharmacia Corp Pharmaceutical composition having reduced tendency for drug crystallization
WO2002056878A2 (en) * 2001-01-18 2002-07-25 Pharmacia Corporation Pharmaceutical composition having reduced tendency for drug crystallization
JP4636796B2 (en) * 2001-08-31 2011-02-23 ノバルティス アーゲー Lumiracoxib-containing pharmaceutical composition
JP2005520785A (en) * 2001-08-31 2005-07-14 ノバルティス アクチエンゲゼルシャフト Lumiracoxib-containing pharmaceutical composition
WO2003026697A2 (en) * 2001-09-26 2003-04-03 Pharmacia Corporation Organoleptically acceptable intraorally disintegrating compositions
WO2003026697A3 (en) * 2001-09-26 2003-07-03 Pharmacia Corp Organoleptically acceptable intraorally disintegrating compositions
WO2003026623A1 (en) * 2001-09-26 2003-04-03 Pharmacia Corporation Intraorally disintegrating valdecoxib compositions
WO2003030876A1 (en) * 2001-10-10 2003-04-17 Pharmacia Corporation Intraorally disintegrating valdecoxib compositions prepared by spray drying process
US7582676B2 (en) 2003-02-13 2009-09-01 Laboratorios Almirall, S.A. 2-phenylpyran-4-one derivatives as selective COX-2 inhibitors
ES2214129A1 (en) * 2003-02-13 2004-09-01 Almirall Prodesfarma, S.A. 3-phenylfuran-2-one derivatives as cox-2 inhibitor
US8541471B2 (en) 2003-05-07 2013-09-24 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
WO2005025564A1 (en) * 2003-09-18 2005-03-24 Nobel Ilac Sanayii A.S Oral pharmaceutical formulations of rofecoxib
US10987337B2 (en) 2018-11-21 2021-04-27 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
US11559509B2 (en) 2018-11-21 2023-01-24 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
US11576890B2 (en) 2018-11-21 2023-02-14 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
US11617735B2 (en) 2018-11-21 2023-04-04 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
US11872206B2 (en) 2018-11-21 2024-01-16 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11858909B2 (en) 2021-04-09 2024-01-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Also Published As

Publication number Publication date
CO5050370A1 (en) 2001-06-27
EE9800393A (en) 1999-06-15
AU3004997A (en) 1997-12-09
PL188649B1 (en) 2005-03-31
KR100373622B1 (en) 2003-07-12
JPH11512754A (en) 1999-11-02
CZ291463B6 (en) 2003-03-12
PL329940A1 (en) 1999-04-26
HUP9902889A3 (en) 2002-04-29
EA001596B1 (en) 2001-06-25
US6063811A (en) 2000-05-16
HK1021623A1 (en) 2000-06-23
EA199801017A1 (en) 1999-04-29
PE66998A1 (en) 1998-10-24
TR199802345T2 (en) 1999-03-22
BG103000A (en) 1999-09-30
IS4891A (en) 1998-11-10
AR012014A1 (en) 2000-09-27
HUP9902889A2 (en) 2002-01-28
SK156798A3 (en) 2000-01-18
EP0910368A1 (en) 1999-04-28
DZ2200A1 (en) 2004-06-20
IL126899A0 (en) 1999-09-22
CN1225010A (en) 1999-08-04
NO985342D0 (en) 1998-11-16
EE03746B1 (en) 2002-06-17
IL126899A (en) 2004-03-28
NO985342L (en) 1998-11-16
SK284330B6 (en) 2005-01-03
CA2254061C (en) 2003-12-02
HRP970262A2 (en) 1998-06-30
CA2254061A1 (en) 1997-11-27
NZ332670A (en) 2000-07-28
BR9709097A (en) 1999-08-03
CN1140267C (en) 2004-03-03
MY116201A (en) 2003-11-28
KR20000011082A (en) 2000-02-25
CZ373898A3 (en) 1999-06-16
ID16921A (en) 1997-11-20

Similar Documents

Publication Publication Date Title
US6063811A (en) Compositions for a once day treatment of cyclooxygenase-2 mediated diseases
FI114913B (en) Process for the preparation of therapeutically useful furanone derivatives and a starting material useful in the process
JPH11501049A (en) Imidazo [1,2-a] pyridine derivative
MXPA01008161A (en) Polymorphic crystalline forms of celecoxib.
JP4206131B2 (en) Combination preparation comprising 5-methylisoxazole-4-carboxylic acid- (4-trifluoromethyl) -anilide and N- (4-trifluoromethylphenyl) -2-cyano-3-hydroxycrotonic acid amide
EP0259990A1 (en) Rapid acting combination of sodium sulindac and a base
KR20040044891A (en) Combinations comprising cox-2 inhibitors and aspirin
WO2002087578A1 (en) Remedial agent for chronic articular rheumatism
TW200823225A (en) New compounds
KR100806684B1 (en) 2-phenylpyran-4-one derivatives
US3993767A (en) Compositions to suppress gastric bleeding in indomethacin and phenylbutazone therapy
JPH0140009B2 (en)
SE453831B (en) NEW 4-PHENYL-4-OXO-2-BUTENIC ACID DERIVATIVES, THEIR SALTS, PREPARATION OF THEM, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1997044027A1 (en) Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
NO315928B1 (en) Use of an anilide compound for the preparation of a prophylactic or therapeutic agent for the treatment of type I allergic diseases
DK154136B (en) METHOD OF ANALOGUE FOR THE PREPARATION OF 2-AMINO-3-BENZOYLPHENYLACETAMIDES
AU775030B2 (en) Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
TW536404B (en) Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
CN109810049B (en) Compound containing pyridine and extraction method thereof
ES2214129A1 (en) 3-phenylfuran-2-one derivatives as cox-2 inhibitor
WO1999014205A1 (en) New 2-(3h)-oxazolone derivatives
EP1090915B1 (en) Polymorphic B form of 3-(cyclopropylmethoxy)-4-¬-4-(methylsulfonyl)phenyl - 5,5-dimethyl-5H-furan-2-one
RU2101011C1 (en) Agent showing analgetic effect
UA51706C2 (en) Method for treating inflammatory diseases by administering 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5h)-furanone
EP0230125A1 (en) Admixtures of diflunisal and tromethamine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-516/98

Country of ref document: YU

Ref document number: 97196315.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 332670

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2254061

Country of ref document: CA

Ref document number: 2254061

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 156798

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 1997 542486

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997924688

Country of ref document: EP

Ref document number: 1019980709239

Country of ref document: KR

Ref document number: PA/a/1998/009588

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PV1998-3738

Country of ref document: CZ

Ref document number: 1998/02345

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 199801017

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 09180647

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997924688

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1998-3738

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019980709239

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019980709239

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: PV1998-3738

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1997924688

Country of ref document: EP